CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
公司代碼CVRX
公司名稱CVRx Inc
上市日期Jun 30, 2021
CEOHykes (Kevin)
員工數量206
證券類型Ordinary Share
年結日Jun 30
公司地址9201 West Broadway Avenue
城市MINNEAPOLIS
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編55445
電話17634162850
網址https://www.cvrx.com/
公司代碼CVRX
上市日期Jun 30, 2021
CEOHykes (Kevin)